HK Stock Market Move | KINTOR PHARMA-B (09939) surged over 7% as the long-term safety trial of KT-939 has been successfully completed, and the company is actively advancing the related registration application work.

KINTOR PHARMA-B (09939) has risen by over 7%. As of the time of this report, it is up 7.14%, priced at HKD 1.95, with a trading volume of HKD 1.1206 million. In news, KINTOR PHARMA-B announced that its self-developed novel and highly effective tyrosinase inhibitor KT-939, aimed at inhibiting melanin production, has successfully completed a long-term safety trial on humans as of September 4, 2026. A total of 114 subjects have used KT-939 continuously for 52 weeks, and preliminary data indicates that no adverse skin reactions were observed, consistent with the interim results from the 28-week clinical use in the trial, demonstrating good safety for KT-939. As a new generation innovative whitening and spot-fading ingredient, KT-939 must be approved by the National Medical Products Administration before it can be marketed. This long-term safety trial was conducted in accordance with the guidelines on "Long-term Human Trial Methods for Cosmetic Ingredients" issued by the regulatory authority on June 18, 2026. The results are one of the most critical components of the registration application materials for KT-939. The company is actively advancing the registration application process for KT-939 and plans to submit all application materials to the regulatory authority as soon as possible following the results of this long-term safety trial.